NAVBQ (Navidea Biopharmaceuticals) YoY EBITDA Growth: 87.85% (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAVBQ Navidea Biopharmaceuticals Inc NAVBQ
16 GF Score
Price $0.00
View Full Analysis

What is Navidea Biopharmaceuticals YoY EBITDA Growth?

Navidea Biopharmaceuticals NAVBQ 16 YoY EBITDA Growth is 87.85% as of Sep. 2023. GuruFocus rates NAVBQ with a GF Score™ of 16/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Navidea Biopharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was 87.85%.

Navidea Biopharmaceuticals's EBITDA per Share for the three months ended in Sep. 2023 was $-0.02.

Navidea Biopharmaceuticals YoY EBITDA Growth Related Terms

Navidea Biopharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Navidea Biopharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navidea Biopharmaceuticals YoY EBITDA Growth Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.53 59.68 41.33 10.91 -14.54

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -129.11 16.81 62.89 70.53 87.85
NAVBQ
16GF Score
Navidea Biopharmaceuticals Inc NAVBQ
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Navidea Biopharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Navidea Biopharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-0.449--0.392)/ | -0.392 |
=-14.54 %

Navidea Biopharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (Q: Sep. 2023 )
=(EBITDA per Share (Q: Sep. 2023 )-EBITDA per Share (Q: Sep. 2022 )) / | EBITDA per Share (Q: Sep. 2022 )) |
=(-0.022--0.181)/ | -0.181 |
=87.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 87.85% mean?
Navidea Biopharmaceuticals (NAVBQ) has a YoY EBITDA Growth of 87.85% as of Sep. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Navidea Biopharmaceuticals and its competitors.
Is Navidea Biopharmaceuticals' YoY EBITDA Growth too high?
Navidea Biopharmaceuticals' current YoY EBITDA Growth is 87.85%. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' YoY EBITDA Growth compare to PKBO and RSPI?
Navidea Biopharmaceuticals' YoY EBITDA Growth of 87.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Navidea Biopharmaceuticals and its competitors. Navidea Biopharmaceuticals's current YoY EBITDA Growth is 87.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current YoY EBITDA Growth of 87.85%. The current YoY EBITDA Growth is 87.85%. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current YoY EBITDA Growth is 87.85% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Navidea Biopharmaceuticals Business Description

Address 4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score

Get the complete analysis for NAVBQ

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price